bradykinin


Also found in: Medical, Acronyms, Encyclopedia, Wikipedia.
Related to bradykinin: Prostaglandins, histamine, kallikrein, substance P

brad·y·ki·nin

 (brăd′ĭ-kī′nĭn, -kĭn′ĭn)
n.
A biologically active polypeptide, consisting of nine amino acids, that forms from a blood plasma globulin and mediates the inflammatory response, increases vasodilation, and causes contraction of smooth muscle.

[brady- + Greek kīnein, to move; see keiə- in Indo-European roots + -in.]

bradykinin

(ˌbrædɪˈkaɪnɪn; ˌbreɪdɪ-)
n
(Physiology) a peptide in blood plasma that dilates blood vessels and causes contraction of smooth muscles. Formula: C50H73N15O11
[C20: from brady- + Greek kin(ēsis) motion + -in]

brad•y•kin•in

(ˌbræd ɪˈkɪn ɪn, -ˈkaɪ nɪn)

n.
a peptide hormone that dilates blood vessels and increases capillary permeability.
[1945–50]
Mentioned in ?
References in periodicals archive ?
Ronald MB, Christopher DH (1990) A bradykinin antagonist inhibits carrageenan edema in rats.
VIENNA -- The investigational bradykinin receptor antagonist icatibant appears to hold considerable therapeutic potential in episodes of hereditary angioedema, Konrad Bork, M.
Combined action of vasoactive amines and bradykinin mediates allergen-evoked thermal hyperalgesia in rats.
Unlike other treatments for HAE, FIRAZYR is the first bradykinin receptor antagonist, offering a unique mechanism of action.
Ra Pharma has discovered HAE drug candidates designed to prevent these attacks by inhibiting plasma kallikrein, which controls the release of bradykinin, a mediator of swelling and pain associated with HAE attacks.
One year of perindopril also resulted in significant upregulation of the enzyme responsible for nitric oxide release, along with a 27% reduction in levels of angiotensin-II, a 17% increase in bradykinin, and a significant reduction in tumor necrosis factor-[alpha].
The complete FAST-3 data demonstrates FIRAZYR's efficacy and safety further illustrating the utility of a bradykinin B2 receptor antagonist to treat acute HAE attacks," said Dr.
Ecallantide produces rapid, specific, and reversible blockade of plasma kallikrein, by inhibiting the plasma kallikrein-mediated cleavage of high-molecular weight kininogen (HMWK), directly affecting the pathways involved in both the upstream mediators of bradykinin production as well as the downstream mediators of degradation, thus preventing the release of bradykinin.
Bradykinin has been shown to be elevated in HAE patients and responsible for edema formation during HAE attacks.
The protein encoded by the claimed sequences is thought to play a role in modulating bradykinin and substance P levels in an individual as well as specifically a role in acquired or inherited angioedema or acute pancreatitis.
Bradykinin is a naturally occurring peptide in the blood and an increase in its levels within the blood causes a widening of spaces within the cell walls of blood vessels, and swelling/ oedema occurs.